PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 10 June 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced, as a result of the closing of its private placement which
raised ?74.2 million on 1 June 2016, the following information in accordance
with article 15 of the Law of 2 May 2007 on the publication of major
shareholdings in issuers whose shares are admitted to trading on a regulated
market (the "Transparency Law").
As of today, Ablynx's total share capital amounts to 113,771,789.41. The total
number of securities conferring voting rights is 60,870,926 which is also the
total number of voting rights (the "denominator"). The total number of rights
(warrants) to subscribe to not yet issued securities conferring voting rights is
2,672,222 which equals the total number of voting rights that may result from
the exercise of these warrants. Currently 1,000 convertible bonds are
outstanding entitling the holders thereof to 7,733,952 shares of the Company in
the aggregate, upon conversion of such convertible bonds.
+-------------------------------------------------------------+---------------+
|Total amount of share capital |?113,771,789.41|
+-------------------------------------------------------------+---------------+
|Total number of securities conferring voting rights |60,870,926 |
+-------------------------------------------------------------+---------------+
|Total number of voting rights (denominator) |60,870,926 |
+-------------------------------------------------------------+---------------+
|Total number of warrants, in number of shares |2,672,222 |
+-------------------------------------------------------------+---------------+
|Maximum additional number of shares after conversion of bonds|7,733,952 |
+-------------------------------------------------------------+---------------+
|Total number of diluted shares |71,277,100 |
+-------------------------------------------------------------+---------------+
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
40 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies including
AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck
Serono, Novartis and Novo Nordisk. The Company is headquartered in Ghent,
Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx(at)fticonsulting.com
pdf format of the press release:
http://hugin.info/137912/R/2019623/749870.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#2019623]
Unternehmensinformation / Kurzprofil:
Datum: 10.06.2016 - 18:00 Uhr
Sprache: Deutsch
News-ID 477044
Anzahl Zeichen: 4545
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 397 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
